Omnicell Stock Fair Value – OMNICELL Reports Second Quarter Fiscal Year 2023 Earnings Results
August 24, 2023
🌥️Earnings Overview
For the second quarter of fiscal year 2023, ending June 30, 2023, OMNICELL ($NASDAQ:OMCL) reported total revenue of USD 299.0 million, which represented a year-on-year decline of 9.8%. The company’s net income for the quarter was USD 3.4 million, a drop of 62.0% compared to the same period in the prior year.
Price History
On Tuesday, OMNICELL reported their second quarter earnings results for fiscal year 2023. The company’s stock opened the day at $63.0 and after a day of trading, it closed at $61.7, representing a 2.3% decrease from the prior closing price of $63.2. This news was met with mixed reactions from investors.
Additionally, the company’s gross margin decreased due to higher product costs, which further impacted investor sentiment. Despite the lower closing price, analysts remain optimistic about OMNICELL’s future prospects. The company’s new product launches are expected to drive further revenue growth in the next quarter and beyond. Additionally, the company’s strategic investments in research and development will likely lead to improved products and services in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Omnicell. More…
| Total Revenues | Net Income | Net Margin |
| 1.24k | -23.18 | -1.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Omnicell. More…
| Operations | Investing | Financing |
| 189 | -61.58 | 20.08 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Omnicell. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.19k | 1.03k | 25.34 |
Key Ratios Snapshot
Some of the financial key ratios for Omnicell are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.9% | 26.3% | -2.8% |
| FCF Margin | ROE | ROA |
| 10.3% | -1.9% | -1.0% |
Analysis – Omnicell Stock Fair Value
At GoodWhale, we have conducted an in-depth analysis of OMNICELL‘s fundamental data. Our proprietary Valuation Line gave us a calculated intrinsic value of around $117.7 per share. This means that OMNICELL’s stock is currently undervalued by 47.6%, as it is currently traded at $61.7. This presents an opportunity for investors to obtain significant upside potential in the near term. More…
Peers
The company’s products are used by hospitals, nursing homes, home health agencies, and other healthcare providers. Omnicell Inc’s competitors include Nexus AG, PrimeCare Systems Inc, 10x Genomics Inc, and other companies that provide similar products and services.
– Nexus AG ($LTS:0FGL)
Nexus AG is a German software company that specializes in enterprise resource planning (ERP) software. The company has a market capitalization of 814.29 million euros as of 2022 and a return on equity of 11.21%. Nexus AG’s main competitors include SAP SE, Oracle Corporation, and Microsoft Corporation.
– PrimeCare Systems Inc ($OTCPK:PCYS)
PrimaCare Systems Inc is a publicly traded company with a market capitalization of $44.19 million as of March 2022. The company has a return on equity of 9.24%. PrimaCare Systems Inc is a healthcare technology company that provides software and services to healthcare providers.
– 10x Genomics Inc ($NASDAQ:TXG)
10x Genomics Inc is a life sciences company that develops and sells products and services for genomic analysis. The company’s products include sequencing services, software, and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
10x Genomics has a market cap of $3.07 billion as of 2022 and a return on equity of -10.81%. The company’s products are used for genomic sequencing and analysis, and its services include software and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
Summary
OMNICELL reported its earnings for the second quarter of 2023, with total revenue of USD 299.0 million, a decrease of 9.8% year-on-year. Net income for the quarter was USD 3.4 million, a decrease of 62.0% compared to the prior year. This is a concerning sign for investors, as it shows a decrease in revenue and profitability.
They should closely monitor the company’s performance in the coming quarters to gauge if their strategy is effective and if their financials are improving. In the meantime, investors should assess the potential risks and consider whether or not OMNICELL is a viable investment.
Related Posts
Recent Posts
